{"ATC Code":"N - Nervous system","Abbreviation":"","Aliases":["Depas","Etizolamum","Sedekopan","Y-7131","AHR 3219","4-(2-chlorophenyl)-2-ethyl-9-methyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine","4-(o-Chlorophenyl)-2-ethyl-9-methyl-6H-thieno(3,2-f)-s-triazolo(4,3-a)(1,4)diazepine","6-(o-Chlorophenyl)-8-ethyl-1-methyl-4H-s-triazolo(3,4-c)thieno(2,3-e)(1,4)-diazepine","6H-Thieno(3,2-f)(1,2,4)triazolo(4,3-a)(1,4)diazepine, 4-(2-chlorophenyl)-2-ethyl-9-methyl-","8-Ethyl-6-(o-chlorophenyl)-1-methyl-4H-s-triazolo(3,4c)thieno(2,3e)-1,4-diazepine"],"Biological Half-Life":"The average elimination half life of etizolam following a single oral dose of 0.5mg is 3.4 hours but may be increased up to 17 hours depending on the rate of metabolism. The main metabolite α-hydroxyetizolam displays a longer elimination half life of 8.2 hours.","CAS":"40054-69-1","ChEBI":"CHEBI:31583","ChEMBL":"CHEMBL1289779","ChemicalClasses":["thienotriazolodiazepine"],"Chirality":"achiral","Classes":null,"DEA no":2780,"Drug Classes":"Breast Feeding; Lactation; Milk, Human; Hypnotics and Sedatives; Anti-Anxiety Agents; Benzodiazepines","Drug Indication":"Indicated for the treatment of generalized anxiety disorder with depression, panic disorder and insomnia.","DrugClasses":["depressant","antipsychotic"],"Erowid Experience Reports":[{"Author":"RogerRabbit22","Id":"100418","Title":"Subtle Peace"},{"Author":"BrainPhuck","Id":"101989","Title":"Powerful, Fun and Useful"},{"Author":"Euslace Nodd","Id":"100899","Title":"Great Sleep-Aid"},{"Author":"AzInoxia","Id":"101899","Title":"More Than I Expected"},{"Author":"higherthanlife","Id":"102535","Title":"The Come Down"},{"Author":"Nipslip420","Id":"102826","Title":"Light as a Feather"},{"Author":"SYA","Id":"102889","Title":"Simple and Fair Analysis"},{"Author":"Chubbus","Id":"102908","Title":"Fun While It Lasted"},{"Author":"Mordecai","Id":"102920","Title":"All Purpose Drug"},{"Author":"PhilipJFry","Id":"103000","Title":"Like a Benzo but a Bit Floatier"},{"Author":"John_Walker","Id":"103052","Title":"Floating in the Tizabiss"},{"Author":"peggyolson","Id":"103068","Title":"Stronger Than You'd Think"},{"Author":"Lady_Codone","Id":"103276","Title":"8th Circle of Hell"},{"Author":"wornoutplaces","Id":"103579","Title":"Pretty Damned Close"},{"Author":"UnForSeen","Id":"103248","Title":"Have Developed a Tolerance"},{"Author":"eachmonth","Id":"103414","Title":"Nothing Unusual About This Drug"},{"Author":"kittenchemist","Id":"103698","Title":"Awoke Feeling Refreshed"},{"Author":"srah","Id":"103780","Title":"Relaxed, Hungry for Sleep and Forgetful"},{"Author":"Thewatchfuleye","Id":"104342","Title":"Great Day"},{"Author":"ErowidLover","Id":"104241","Title":"Chilling With the Blue Pill"},{"Author":"kushedgy","Id":"104406","Title":"Overthinking Social Anxiety"},{"Author":"OrganicJunkie","Id":"104533","Title":"Love-hate Relationship With This Love of Mine"},{"Author":"AP","Id":"104635","Title":"Getting to Know You"},{"Author":"Alex166663851","Id":"104805","Title":"A Day and a Half Gone"},{"Author":"BenzoAdvocate","Id":"105170","Title":"The Same Substance in a Different Medium"},{"Author":"All_Apologies","Id":"105732","Title":"Pipedream Walker"}],"European Community (EC) Number":"662-368-4","HMDB ID":"HMDB0041890","HeavyAtomCount":23,"Human Drugs":"Breast Feeding; Lactation; Milk, Human; Hypnotics and Sedatives; Anti-Anxiety Agents; Benzodiazepines","IUPACName":"7-(2-chlorophenyl)-4-ethyl-13-methyl-3-thia-1,8,11,12-tetrazatricyclo[8.3.0.02,6]trideca-2(6),4,7,10,12-pentaene","InChI":"InChI=1S/C17H15ClN4S/c1-3-11-8-13-16(12-6-4-5-7-14(12)18)19-9-15-21-20-10(2)22(15)17(13)23-11/h4-8H,3,9H2,1-2H3","InChIKey":"VMZUTJCNQWMAGF-UHFFFAOYSA-N","MeSH Pharmacological Classification":"A traditional grouping of drugs said to have a soothing or calming effect on mood, thought, or behavior. Included here are the ANTI-ANXIETY AGENTS (minor tranquilizers), ANTIMANIC AGENTS, and the ANTIPSYCHOTIC AGENTS (major tranquilizers). These drugs act by different mechanisms and are used for different therapeutic purposes. (See all compounds classified as Tranquilizing Agents.)","Melting Point":"147-148","MolecularFormula":"C\u003csub\u003e17\u003c/sub\u003eH\u003csub\u003e15\u003c/sub\u003eClN\u003csub\u003e4\u003c/sub\u003eS","MolecularWeight":"342.8 g/mol","Pharmacodynamics":"Etizolam is a CNS depressant with anxiolytic, anticonvulsant, sedative-hypnotic and muscle relaxant effects. It acts on the benzodiazepine site of the GABA-A receptor as an agonist to increase inhibitory GABAergic transmission throughout the central nervous system. Studies indicate that etizolam mediates its pharmacological actions with 6 to 10 times more potency than that of diazepam. Clinical human studies performed in Italy showed clinical effectiveness of etizolam in relieving symptoms in patients with generalized anxiety disorders with depressive symptoms. Etizolam also mediates imipramine-like neuropharmacological and behavioral effects, as well as minor effects on cognitive functioning. It is shown to substitute the actions of a short-acting barbiturate, pentobarbitol, in a drug discrimination study.  Etizolam is an antagonist at platelet-activating-factor (PAF) receptor and attenuates the recurrence of chronic subdural hematoma after neurosurgery in clinical studies. It is shown to inhibit PAF-induced bronchoconstriction and hypotension.","PrevSalts":[],"PubChemId":3307,"Record Description":["Etizolam is an organic molecular entity.","Etizolam is a thienodiazepine which is chemically related to benzodiazepine (BDZ) drug class; it differs from BDZs in having a benzene ring replaced with a thiophene ring. It is an agonist at GABA-A receptors and possesses amnesic, anxiolytic, anticonvulsant, hypnotic, sedative and skeletal muscle relaxant properties. Initially introduced in 1983 in Japan as treatment for neurological conditions such as anxiety and sleep disorders, etizolam is marketed in Japan, Italy and India. It is not approved for use by FDA in the US; however it remains unscheduled in several states and is legal for research purposes.","ETIZOLAM is a small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.","According to the Italian P.I. sheet etizolam belongs to a new class of diazepines, thienotriazolodiazepines. This new class is easily oxidized, rapidly metabolized, and has a lower risk of accumulation, even after prolonged treatment. Etizolam has an anxiolytic action about 6 times greater than that of diazepam. Etizolam produces, especially at higher dosages, a reduction in time taken to fall asleep, an increase in total sleep time and a reduction in the number of awakenings. During tests there were not substantial changes in deep sleep. There is a reduction of REM sleep. In EEG tests of healthy volunteers Etizolam showed some characteristics of tricyclic antidepressants. Etizolam (marketed under the brand name Etilaam, Etizola, Sedekopan, Pasaden or Depas) is a thienodiazepine drug which is a benzodiazepine analog. The etizolam molecule differs from a benzodiazepine in that the benzene ring has been replaced by a thiophene ring. It possesses amnesic, anxiolytic, anticonvulsant, hypnotic, sedative and skeletal muscle relaxant properties.","Etizolam is an organic molecular entity.","Wikipedia|List of designer drugs|Sedatives|Thienodiazepines"],"RefCount":3,"References":[{"Name":"Wikipedia","Urls":[{"Link":"https://en.wikipedia.org/wiki/Etizolam","Name":"Etizolam","Sub":false}]},{"Name":"Wikidata","Urls":[{"Link":"https://www.wikidata.org/wiki/Q409966","Name":"Etizolam","Sub":false}]},{"Name":"DrugBank","Urls":[{"Link":"https://go.drugbank.com/drugs/DB09166","Name":"Etizolam","Sub":false}]},{"Name":"PubChem","Urls":[{"Link":"https://pubchem.ncbi.nlm.nih.gov/compound/3307","Name":"Etizolam","Sub":false}]},{"Name":"ChEMBL","Urls":[{"Link":"https://www.ebi.ac.uk/chembl/explore/compound/CHEMBL1289779","Name":"Etizolam","Sub":false}]},{"Name":"ChEBI","Urls":[{"Link":"https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:31583","Name":"Etizolam","Sub":false}]},{"Name":"Common Chemistry","Urls":[{"Link":"https://commonchemistry.cas.org/detail?cas_rn=40054-69-1","Name":"Etizolam","Sub":false}]},{"Name":"HMDB","Urls":[{"Link":"https://hmdb.ca/metabolites/HMDB0041890","Name":"Etizolam","Sub":false}]},{"Name":"KEGG","Urls":[{"Link":"https://www.kegg.jp/entry/D01514","Name":"Etizolam","Sub":false}]},{"Name":"UNII","Urls":[{"Link":"https://gsrs.ncats.nih.gov/ginas/app/ui/substances/A76XI0HL37","Name":"Etizolam","Sub":false}]},{"Name":"EPA DSSTox","Urls":[{"Link":"https://comptox.epa.gov/dashboard/chemical/details/DTXSID0023030","Name":"Etizolam","Sub":false}]}],"Refs":["National Center for Biotechnology Information. PubChem Compound Summary for CID 3307, Etizolam. Accessed June 26, 2025. \u003ca href=https://pubchem.ncbi.nlm.nih.gov/compound/3307\u003ehttps://pubchem.ncbi.nlm.nih.gov/compound/3307\u003c/a\u003e","U.S. Food and Drug Administration; National Center for Advancing Translational Sciences. Etizolam. UNII: A76XI0HL37. Global Substance Registration System. Accessed June 26, 2025. \u003ca href=https://gsrs.ncats.nih.gov/ginas/app/beta/substances/A76XI0HL37\u003ehttps://gsrs.ncats.nih.gov/ginas/app/beta/substances/A76XI0HL37\u003c/a\u003e"],"SMILES":"CCC1=CC2=C(S1)N3C(=NN=C3CN=C2C4=CC=CC=C4Cl)C","Solubility":"Practically insoluble","StoreUNII":["A76XI0HL37"],"StructureBase64":"<svg xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" height="104.213mm" version="1.2" viewBox="0 0 85.378 104.213" width="85.378mm">
      
    <desc>Generated by the Chemistry Development Kit (http://github.com/cdk)</desc>
      
    <g fill="#3050F8" stroke="#000000" stroke-linecap="round" stroke-linejoin="round" stroke-width=".7">
            
        <rect fill="#FFFFFF" height="105.0" stroke="none" width="86.0" x=".0" y=".0"/>
            
        <g class="mol" id="mol1">
                  
            <line class="bond" id="mol1bnd1" x1="1.038" x2="8.658" y1="54.492" y2="41.294"/>
                  
            <line class="bond" id="mol1bnd2" x1="8.658" x2="23.898" y1="41.294" y2="41.294"/>
                  
            <g class="bond" id="mol1bnd3">
                        
                <line x1="23.898" x2="32.839" y1="41.294" y2="53.587"/>
                        
                <line x1="26.913" x2="33.773" y1="41.294" y2="50.725"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd4" x1="32.839" x2="47.368" y1="53.587" y2="48.914"/>
                  
            <g class="bond" id="mol1bnd5">
                        
                <line x1="47.368" x2="47.368" y1="48.914" y2="33.674"/>
                        
                <line x1="44.929" x2="44.929" y1="47.137" y2="35.451"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd6" x1="47.368" x2="35.707" y1="33.674" y2="29.923"/>
                  
            <line class="bond" id="mol1bnd7" x1="23.898" x2="30.471" y1="41.294" y2="32.257"/>
                  
            <line class="bond" id="mol1bnd8" x1="47.368" x2="56.223" y1="33.674" y2="26.559"/>
                  
            <line class="bond" id="mol1bnd9" x1="58.925" x2="57.95" y1="20.279" y2="8.939"/>
                  
            <g class="bond" id="mol1bnd10">
                        
                <line x1="68.76" x2="57.95" y1="4.374" y2="8.939"/>
                        
                <line x1="69.709" x2="60.531" y1="6.62" y2="10.496"/>
                      
                <line class="hi" stroke="#3050F8" x1="68.76" x2="63.355000000000004" y1="4.374" y2="6.656499999999999"/>
                <line class="hi" stroke="#3050F8" x1="69.709" x2="65.12" y1="6.62" y2="8.558"/>
            </g>
                  
            <line class="bond" id="mol1bnd11" x1="74.848" x2="79.11" y1="6.31" y2="11.232"/>
                  
            <g class="bond" id="mol1bnd12">
                        
                <line x1="74.089" x2="79.764" y1="27.578" y2="18.181"/>
                        
                <line x1="72.917" x2="77.677" y1="24.801" y2="16.92"/>
                      
                <line class="hi" stroke="#3050F8" x1="79.764" x2="76.9265" y1="18.181" y2="22.8795"/>
                <line class="hi" stroke="#3050F8" x1="77.677" x2="75.297" y1="16.92" y2="20.860500000000002"/>
            </g>
                  
            <line class="bond" id="mol1bnd13" x1="62.559" x2="74.089" y1="24.893" y2="27.578"/>
                  
            <line class="bond" id="mol1bnd14" x1="74.089" x2="80.693" y1="27.578" y2="41.294"/>
                  
            <line class="bond" id="mol1bnd15" x1="80.693" x2="75.875" y1="41.294" y2="51.298"/>
                  
            <g class="bond" id="mol1bnd16">
                        
                <line x1="59.255" x2="70.784" y1="58.464" y2="55.779"/>
                        
                <line x1="59.857" x2="70.231" y1="55.82" y2="53.404"/>
                      
                <line class="hi" stroke="#3050F8" x1="70.784" x2="65.01950000000001" y1="55.779" y2="57.1215"/>
                <line class="hi" stroke="#3050F8" x1="70.231" x2="65.044" y1="53.404" y2="54.612"/>
            </g>
                  
            <line class="bond" id="mol1bnd17" x1="47.368" x2="59.255" y1="48.914" y2="58.464"/>
                  
            <line class="bond" id="mol1bnd18" x1="59.255" x2="55.87" y1="58.464" y2="73.323"/>
                  
            <g class="bond" id="mol1bnd19">
                        
                <line x1="55.87" x2="41.263" y1="73.323" y2="77.83"/>
                        
                <line x1="55.244" x2="43.342" y1="76.068" y2="79.741"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd20" x1="41.263" x2="38.013" y1="77.83" y2="92.72"/>
                  
            <g class="bond" id="mol1bnd21">
                        
                <line x1="38.013" x2="49.149" y1="92.72" y2="103.158"/>
                        
                <line x1="40.69" x2="49.777" y1="91.887" y2="100.404"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd22" x1="49.149" x2="63.778" y1="103.158" y2="98.552"/>
                  
            <g class="bond" id="mol1bnd23">
                        
                <line x1="63.778" x2="67.028" y1="98.552" y2="83.662"/>
                        
                <line x1="61.697" x2="64.348" y1="96.651" y2="84.504"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd24" x1="55.87" x2="67.028" y1="73.323" y2="83.662"/>
                  
            <line class="bond" id="mol1bnd25" x1="67.028" x2="78.38" y1="83.662" y2="80.097"/>
                  
            <line class="bond" id="mol1bnd26" x1="57.95" x2="44.9" y1="8.939" y2="1.068"/>
                  
            <path class="atom" d="M34.384 30.137q-.0 .649 -.476 1.018q-.471 .363 -1.268 .363q-.417 .0 -.768 -.065q-.346 -.06 -.578 -.173v-.589q.244 .113 .607 .202q.369 .089 .762 .089q.548 .0 .828 -.214q.28 -.214 .28 -.577q-.0 -.238 -.108 -.399q-.101 -.167 -.351 -.31q-.25 -.143 -.696 -.297q-.625 -.227 -.947 -.554q-.315 -.333 -.315 -.899q-.0 -.393 .196 -.667q.203 -.279 .554 -.428q.357 -.155 .815 -.155q.405 -.0 .739 .077q.339 .072 .613 .197l-.197 .53q-.25 -.114 -.547 -.185q-.298 -.077 -.626 -.077q-.458 -.0 -.69 .196q-.232 .197 -.232 .518q-.0 .244 .101 .411q.107 .166 .339 .297q.232 .125 .631 .28q.429 .155 .727 .34q.297 .178 .452 .434q.155 .25 .155 .637z" fill="#C6C62C" id="mol1atm7" stroke="none"/>
                  
            <path class="atom" d="M61.196 26.573h-.721l-2.619 -4.066h-.03q.012 .238 .03 .595q.024 .358 .024 .733v2.738h-.566v-4.899h.715l2.607 4.054h.03q-.006 -.107 -.018 -.328q-.012 -.22 -.024 -.476q-.006 -.262 -.006 -.482v-2.768h.578v4.899z" id="mol1atm8" stroke="none"/>
                  
            <path class="atom" d="M73.932 5.459h-.721l-2.619 -4.066h-.03q.012 .239 .03 .596q.024 .357 .024 .732v2.738h-.566v-4.899h.715l2.607 4.054h.03q-.006 -.107 -.018 -.327q-.012 -.221 -.024 -.477q-.006 -.262 -.006 -.482v-2.768h.578v4.899z" id="mol1atm10" stroke="none"/>
                  
            <path class="atom" d="M83.908 16.982h-.72l-2.62 -4.066h-.029q.012 .238 .029 .595q.024 .358 .024 .733v2.738h-.565v-4.899h.714l2.608 4.054h.029q-.006 -.107 -.018 -.328q-.011 -.22 -.023 -.476q-.006 -.262 -.006 -.482v-2.768h.577v4.899z" id="mol1atm11" stroke="none"/>
                  
            <path class="atom" d="M76.029 57.459h-.72l-2.619 -4.066h-.03q.012 .239 .03 .596q.023 .357 .023 .732v2.738h-.565v-4.899h.714l2.608 4.054h.029q-.005 -.107 -.017 -.327q-.012 -.221 -.024 -.477q-.006 -.262 -.006 -.482v-2.768h.577v4.899z" id="mol1atm14" stroke="none"/>
                  
            <path class="atom" d="M82.062 77.12q-.786 -.0 -1.239 .53q-.452 .524 -.452 1.446q.0 .911 .417 1.447q.422 .53 1.268 .53q.321 -.0 .607 -.054q.292 -.059 .566 -.143v.536q-.274 .101 -.566 .149q-.292 .053 -.697 .053q-.744 .0 -1.25 -.309q-.5 -.31 -.75 -.875q-.25 -.572 -.25 -1.34q.0 -.744 .268 -1.309q.274 -.566 .804 -.881q.53 -.322 1.28 -.322q.78 .0 1.351 .286l-.244 .524q-.226 -.101 -.506 -.185q-.274 -.083 -.607 -.083zM84.818 81.543h-.601v-5.215h.601v5.215z" fill="#1FF01F" id="mol1atm22" stroke="none"/>
                
            <line class="hi" id="mol1bnd6" stroke="#C6C62C" x1="35.707" x2="41.5375" y1="29.923" y2="31.798499999999997"/>
            <line class="hi" id="mol1bnd7" stroke="#C6C62C" x1="30.471" x2="27.1845" y1="32.257" y2="36.775499999999994"/>
            <line class="hi" id="mol1bnd8" stroke="#3050F8" x1="56.223" x2="51.795500000000004" y1="26.559" y2="30.116500000000002"/>
            <line class="hi" id="mol1bnd9" stroke="#3050F8" x1="58.925" x2="58.4375" y1="20.279" y2="14.609"/>
            <line class="hi" id="mol1bnd11" stroke="#3050F8" x1="74.848" x2="76.979" y1="6.31" y2="8.770999999999999"/>
            <line class="hi" id="mol1bnd11" stroke="#3050F8" x1="79.11" x2="76.979" y1="11.232" y2="8.770999999999999"/>
            <line class="hi" id="mol1bnd13" stroke="#3050F8" x1="62.559" x2="68.324" y1="24.893" y2="26.235500000000002"/>
            <line class="hi" id="mol1bnd15" stroke="#3050F8" x1="75.875" x2="78.28399999999999" y1="51.298" y2="46.296"/>
            <line class="hi" id="mol1bnd25" stroke="#1FF01F" x1="78.38" x2="72.70400000000001" y1="80.097" y2="81.87950000000001"/>
        </g>
          
    </g>
    
</svg>
","Subjective Effects":null,"Title":"Etizolam","UNII":"A76XI0HL37","Wikidata":"Q409966","Wikipedia":"Etizolam","XLogP":2.6}